These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672 [TBL] [Abstract][Full Text] [Related]
25. New oral drugs for multiple sclerosis. Gasperini C; Ruggieri S Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371 [TBL] [Abstract][Full Text] [Related]
26. [Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis(review)]. Boĭko AN; Gusev EI Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):93-9. PubMed ID: 23675607 [TBL] [Abstract][Full Text] [Related]
27. Fingolimod for relapsing multiple sclerosis: an update. Horga A; Castilló J; Montalban X Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536 [TBL] [Abstract][Full Text] [Related]
28. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711 [TBL] [Abstract][Full Text] [Related]
33. [Therapeutic indications targeting etiology. (With the exception of primary progressive forms)]. Brassat D Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1014-28. PubMed ID: 11787332 [TBL] [Abstract][Full Text] [Related]
34. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945 [TBL] [Abstract][Full Text] [Related]
35. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Huggins A; Sergott RC Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305 [No Abstract] [Full Text] [Related]
36. The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials. Rouhi F; Mohammadpour Z; Noureini SK; Abbastabar H; Harirchian MH; Bitarafan S Eur J Clin Pharmacol; 2020 May; 76(5):611-622. PubMed ID: 32020320 [TBL] [Abstract][Full Text] [Related]
37. Clinical evaluation of natalizumab for formulary consideration. Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228 [TBL] [Abstract][Full Text] [Related]
38. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Martin R Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868 [TBL] [Abstract][Full Text] [Related]
39. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. D'Amico E; Messina S; Caserta C; Patti F Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609 [TBL] [Abstract][Full Text] [Related]